|Mr. Dominick C. Colangelo Esq.||Chief Exec. Officer, Pres, Treasurer and Director||789.04k||N/A||1964|
|Mr. Gerard J. Michel MS, MBA||Chief Financial Officer and VP of Corp. Devel.||507.74k||N/A||1963|
|Mr. Daniel R. Orlando||Chief Operating Officer||460.14k||N/A||1965|
|Ms. Jacquelyn Fahey Sandell||VP, Gen. Counsel and Corp. Sec.||N/A||N/A||N/A|
|Ms. Heidi Hassen||Sr. Director of HR||N/A||N/A||N/A|
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Vericel Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.